Unique ID issued by UMIN | UMIN000017734 |
---|---|
Receipt number | R000020534 |
Scientific Title | A clinical trial for the validation of safety and efficacy of the implant-type tissue-engineered cartilage using autologous cells. |
Date of disclosure of the study information | 2015/06/18 |
Last modified on | 2020/06/17 10:43:16 |
A clinical trial for the validation of safety and efficacy of the implant-type tissue-engineered cartilage using autologous cells.
A clinical trial of the implant-type tissue-engineered cartilage using autologous cells.
A clinical trial for the validation of safety and efficacy of the implant-type tissue-engineered cartilage using autologous cells.
A clinical trial of the implant-type tissue-engineered cartilage using autologous cells.
Japan |
Severe nasal deformity in orofacial cleft, that needs nasal augmentation and nasal tip correction
Oral surgery |
Others
NO
Safety, and collaterally, efficacy of FSI 2007, the implant-type tissue-engineered cartilage using autologous cells, are to be validated by applying it to patients of orofacial cleft with nasal deformities.
Safety
Exploratory
Not applicable
Occurrence and details of all adverse events, those related to the investigative product, and defect of the product are evaluated to validate safety.
Indices such as the distance from nasal tip to nasal root, the area of nose, evaluation of the appearance of whole face and nose/mouth, cosmetic satisfaction, change in daily activity, change in depressiveness, evaluation of the cartilage collection site, evaluation of nasal curvature, evaluation of hardness of the transplantation site, and evaluation of fixing and cartilage maturation by MRI are used exploratory to evaluate the efficacy.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Other |
Transplantation of the implant-type tissue-engineered cartilage using autologous cells
20 | years-old | <= |
Not applicable |
Male and Female
Patients meeting all of criteria below will be included.
1. Patients with nasal deformities in orofacial cleft, that needs nasal augmentation and nasal tip correction
2. Patients who can keep the schedule of observation and investigation described in the protocol of this clinical trial.
3. Patients of age 20 or older (on obtainment of informed consent)
4. Patients who can understand the content of this clinical trial and agree to the written informed consent.
Patients who meet any of the following criteria are excluded.
1. Patients from whom sufficient blood cannot be collected (e.g. by recent blood donation).
2. ASA physical status 3 or worse.
3. Existing or possible malignancy.
4. Uncontrolled diabetes.
5. Possible sepsis.
6. Recurrent skin infection at the surgical sites, e.g. ears or noses.
7. Patients who received, or will undergo surgeries at the operative sites within 1 year before surgery in this trial.
8. Females with existing or possible pregnancy, lactating, or who cannot agree with anticonception until 6 months after the transplantation of FSI2007.
9. Patients found positive in allergy test for atelocollagen
10. Possible syphilis, B/C hepatitis, HIV infection or adult T cell lymphoma.
11. Present, past or family histories of autoimmune diseases, e.g. rheumatoid arthritis, psoriatic arthritis, systemic/discoid lupus erythematosus, dermatomyositis, polymyositis, chronic thyroiditis, Graves' disease, polyartritis, scleroderma, ulcerous colitis, Crohn's disease, Sjogren's syndrome, Reiter syndrome, mixed connective tissue disease or relapsing polychondritis.
12. Histories of anaphylaxia.
13. Histories or possibilities of hypersensitivity or allergy to collagen products, lactic acid polymer, fibroblast growth factor (FGF), insulin, penicillin or streptomycin.
14. Patients who used or will use FGF-2, parathyroid hormone, insulin-like growth factor-I, insulin, growth hormone, female hormones (except cosmetics), male hormones, interleukin-1 receptor antagonist, thyroid hormone, vitamin D (except supplements) or steroids (except topical products) 3 months before blood collection.
15. Patients who were in other clinical trials or clinical researches within 30 days before the obtainment of the consent.
16. Patients with mental diseases who cannot fill out survey slips.
17. Patients judged to be inappropriate as subjects of this trial by the responsive doctor or assigned doctors.
2
1st name | Kazuto |
Middle name | |
Last name | Hoshi |
The University of Tokyo Hospital
The Department of Oral-Maxillofacial Surgery and Orthodontics
113-8655
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 JAPAN
03-3815-5411
pochi-tky@umin.ac.jp
1st name | Kazuto |
Middle name | |
Last name | Hoshi |
The University of Tokyo Hospital
The Department of Oral-Maxillofacial Surgery and Orthodontics
113-8655
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 JAPAN
03-3815-5411
pochi-tky@umin.net
The University of Tokyo Hospital
Japan Agency for Medical Research and Development
Japanese Governmental office
Japan
Institutional Review Board, the University of Tokyo Hospital
7-3-1 Hongo, Bunkyo-ku, Tokyo
03-5800-8743
crctky-office@umin.ac.jp
NO
東京大学医学部附属病院(東京都)
2015 | Year | 06 | Month | 18 | Day |
Unpublished
2
Delay expected |
The application for approval is in progress.
Completed
2015 | Year | 03 | Month | 23 | Day |
2015 | Year | 03 | Month | 19 | Day |
2015 | Year | 06 | Month | 18 | Day |
2019 | Year | 03 | Month | 26 | Day |
2015 | Year | 05 | Month | 29 | Day |
2020 | Year | 06 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020534